The Pfizer-Allergan Pharmaceutical Monopoly: Tax Inversions and Potential Drug Price Hike

The ink is not yet dry on Martin Shkreli’s widely panned decision to raise Daraprim’s price by 5,000%, then comes the news about the Pfizer-Allergan merger. It’s the largest of its kind in history, in more ways than one. This is because of something called inversion, which involves a company’s headquarters transferring to a country […]

The Pfizer-Allergan Pharmaceutical Monopoly: Tax Inversions and Potential Drug Price Hike Read More »